Nasdaq IPOs

Seven IPOs and 10 SPACs went public this past week. The IPO pipeline remained active, with 11 IPOs and 22 SPACs submitting initial filings. Phase 2 biotech Kronos Bio (KRON) priced above the range to raise $250 million at a $1.1 billion market cap. The biotech is developing ther

Spartan Acquisition II, the second blank check company formed by Apollo Global Management targeting the North American energy industry, filed on Friday with the SEC to raise up to $400 million in an initial public offering. The New York-based company plans to raise $400 mill

Yellowstone Acquisition, a blank check company formed by Boston Omaha Corp. targeting the financial and real estate sectors, lowered the proposed deal size for its upcoming IPO on Friday. The Omaha, NE-based company now plans to raise $150 million by offering 15 million units at

Lux Health Tech Acquisition, a blank check company formed by Lux Capital targeting a healthtech business, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans to raise $300 million by offering 30 million unit

SQZ Biotechnologies, a Phase 1 biotech developing cell therapies for solid tumors and other indications, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company is developing cell therapies for cancer, infectious diseases, and other

Tarsus Pharmaceuticals, a Phase 3 biotech developing therapies for ophthalmic conditions, announced terms for its IPO on Friday. The Irvine, CA-based company plans to raise $80 million by offering 5 million shares at a price range of $15 to $17. At the midpoint of the proposed ra

Aligos Therapeutics, a Phase 1 biotech developing oligonucleotide therapies for viral and liver diseases, announced terms for its IPO on Friday. The South San Francisco, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At

Eargo, which manufactures differentiated hearing aid systems, announced terms for its IPO on Friday. The San Jose, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Eargo would comman

Carney Technology Acquisition II, a blank check company targeting the technology industry, filed on Friday with the SEC to raise up to $350 million in an initial public offering. The Burlingame, CA-based company plans to raise $350 million by offering 35 million units at $10

Seven IPOs and 10 SPACs went public this past week. The IPO pipeline remained active, with eight IPOs and seventeen SPACs submitting initial filings. Phase 2 biotech Kronos Bio (KRON) priced above the range to raise $250 million at a $1.1 billion market cap. The biotech is devel

Opthea, an Australian Phase 3 biotech developing VEGF inhibitors for wet AMD, announced terms for its IPO on Friday. The South Yarra, Australia-based company plans to raise $161 million by offering 9.3 million ADSs at $17.26, the as-converted last close of its shares on the ASX (

Atea Pharmaceuticals, a clinical stage biotech developing therapies for COVID-19 and other viral infections, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Atea Pharmaceuticals is developing antiviral therapeutics for life-threatening&nbsp

Vivos Therapeutics, which is developing medical devices for sleep disordered breathing, filed on Friday with the SEC to raise up to $20 million in an initial public offering. The Highlands Ranch, CO-based company plans to raise $20 million by offering 3.3 million shares at a pric

Ajax I, a blank check company formed by Och-Ziff's Daniel Och and MSD Capital's Glenn Fuhrman, filed on Friday with the SEC to raise up to $750 million in an initial public offering. The New York, NY-based company plans to raise $750 million by offering 75 million units at $10. E

Ajax I, a blank check company formed by Och-Ziff's Daniel Och and MSD Capital's Glenn Fuhrman, filed on Friday with the SEC to raise up to $750 million in an initial public offering. The New York, NY-based company plans to raise $750 million by offering 75 million units at $10. E

Mudrick Capital Acquisition II, the second blank check company formed by distressed debt investor Jason Mudrick to acquire a post-bankruptcy business, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans

Intrusion, which provides a family of software products for enterprise security, raised $25 million by offering 3.1 million shares (65% primary) at $8, below the last close of its shares on the OTCQB (INTZ). At pricing, the company commands a market value of $135 million. Intrusi

Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $126 million by offering 7.4 million shares at a price range of $16 to $18. At the mi

Consonance-HFW Acquisition, a blank check company formed by Consonance Capital targeting the life science industry, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Princeton, NJ-based company plans to raise $100 million by offering 10 m

Shattuck Labs, a Phase 1 biotech developing novel dual-sided fusion protein therapies for cancer, raised $202 million by offering 11.9 million shares at $17, above the range of $14 to $16. The company offered 1.9 million more shares than anticipated. At pricing, the company raise